Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This study is for patients who have a high risk of metastatic prostate cancer (cancer that
has spread outside of the prostate) who are going to have radical prostatectomy. The
Anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (FACBC or Fluciclovine) positron
emission tomography (PET) scan is a new imaging approach that has promising results in
showing progression of cancer. The goal of this study is to determine if FACBC PET imaging
will detect metastatic disease in patients with high risk prostate cancer who have negative
conventional cross-sectional imaging such as computed tomography (CT) and/or magnetic
resonance imaging (MRI), as well as bone scan and/or sodium fluoride PET. FACBC PET imaging
may help detect metastatic prostate cancer in patients with newly diagnosed high risk primary
prostate cancer and potentially improve staging of the cancer. Additionally, the researchers
will compare the FACBC uptake in the prostate with uptake of FACBC detected in metastasis.
They will also analyze and compare the prostate tissue, serum and urine parameters that are
linked to higher rates of FACBC positivity.